Revolution Medicines, Inc. ((RVMD)), Tango Therapeutics, Inc. ((TNGX)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Revolution Medicines, Inc. and Tango Therapeutics, Inc. are conducting a clinical study titled ‘A Phase 1/2, Multicenter, Open-Label Study to Evaluate Safety, Tolerability & Antitumor Activity of TNG462 in Combination With Other Agents in Patients With Pancreatic or Non-Small Cell Lung Cancer With MTAP Loss & RAS Mutation.’ The study aims to assess the safety, tolerability, and preliminary antitumor activity of TNG462 combined with RMC-6236 or RMC-9805 in patients with specific genetic mutations. This research is significant as it targets challenging cancer types with limited treatment options.
The interventions being tested are oral drugs: TNG462, an MTA cooperative PRMT5 inhibitor, RMC-9805, a RAS(ON) G12D selective covalent inhibitor, and RMC-6236, a RAS(ON) multi-selective inhibitor. These drugs are designed to target specific mutations in cancer cells, potentially improving treatment outcomes.
The study follows a non-randomized, sequential intervention model with no masking, focusing on treatment. It includes a dose escalation phase to determine the optimal doses, followed by a dose expansion phase to further evaluate the drug combinations in patients with MTAP loss and RAS mutations.
The study began on March 28, 2025, with the latest update on August 29, 2025. These dates are crucial as they indicate the study’s progress and the timeline for potential results.
This clinical update could positively influence the stock performance of both Revolution Medicines and Tango Therapeutics by demonstrating progress in developing targeted cancer therapies. Investors may view this as a promising advancement in the oncology sector, potentially impacting market sentiment favorably.
The study is currently recruiting, with further details available on the ClinicalTrials portal.